Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Rogier Hintzen, Gavin Giovannoni et al.|The Lancet Neurology|2019Cited by 185
Metabolomic signatures associated with disease severity in multiple sclerosisPablo Villoslada, Azucena Castro, Cristina Alonso et al.|Neurology Neuroimmunology & Neuroinflammation|2017Cited by 111
Teriflunomide added to interferon-β in relapsing multiple sclerosisM. S. Freedman, K. Ton, Jerry S. Wolinsky et al.|Neurology|2012Cited by 78